Unshackling caspase-7 for cancer therapy.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 23979156.
- Also identified by DOI 10.1172/JCI71440 and PMC identifier 3754280.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Numerous solid tumors and hematologic malignancies acquire resistance to apoptosis-inducing chemotherapeutic drugs by downregulating the key effector caspase-3. These cells rely on caspase-7 to execute the apoptotic program, yet binding with XIAP constitutively inhibits active caspase-7 (p19/p12-CASP7). In this issue, Lin et al. describe how a newly synthesized drug is able to disrupt the XIAP:p19/p12-CASP7 complex and induce apoptosis in caspase-3-deficient cancer cells in vitro and in vivo. As this compound appears to exhibit minimal toxicity on normal tissues, it may represent a promising therapeutic agent to help treat caspase-3-deficient tumors.
Medical subject headings
- Antineoplastic Agents
- Caspase 3
- Caspase 7
- Drug Resistance, Neoplasm
- Lysine
- X-Linked Inhibitor of Apoptosis Protein